- Home
- GNLX vs SGMO Comparison
GNLX vs SGMO Comparison
Compare GNLX & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- SGMO
- Stock Information
- Founded
- GNLX 2001
- SGMO 1995
- Country
- GNLX United States
- SGMO United States
- Employees
- GNLX N/A
- SGMO N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNLX Health Care
- SGMO Health Care
- Exchange
- GNLX Nasdaq
- SGMO Nasdaq
- Market Cap
- GNLX 128.0M
- SGMO 122.8M
- IPO Year
- GNLX 2023
- SGMO 2000
- Fundamental
- Price
- GNLX $5.31
- SGMO $0.74
- Analyst Decision
- GNLX Strong Buy
- SGMO Strong Buy
- Analyst Count
- GNLX 4
- SGMO 7
- Target Price
- GNLX $17.75
- SGMO $5.29
- AVG Volume (30 Days)
- GNLX 134.5K
- SGMO 5.6M
- Earning Date
- GNLX 11-13-2025
- SGMO 11-11-2025
- Dividend Yield
- GNLX N/A
- SGMO N/A
- EPS Growth
- GNLX N/A
- SGMO N/A
- EPS
- GNLX N/A
- SGMO N/A
- Revenue
- GNLX N/A
- SGMO $81,706,000.00
- Revenue This Year
- GNLX N/A
- SGMO $28.47
- Revenue Next Year
- GNLX N/A
- SGMO N/A
- P/E Ratio
- GNLX N/A
- SGMO N/A
- Revenue Growth
- GNLX N/A
- SGMO 565.52
- 52 Week Low
- GNLX $1.99
- SGMO $0.41
- 52 Week High
- GNLX $5.89
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- GNLX 79.41
- SGMO 72.04
- Support Level
- GNLX $4.17
- SGMO $0.65
- Resistance Level
- GNLX $4.83
- SGMO $0.73
- Average True Range (ATR)
- GNLX 0.29
- SGMO 0.06
- MACD
- GNLX 0.07
- SGMO 0.01
- Stochastic Oscillator
- GNLX 95.62
- SGMO 89.26
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.